A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study ...
As COVID-19 numbers surge once again across California, new research out of UCSF has found that Paxlovid, the go-to treatment for the virus, does not have any beneficial effect on those suffering from ...
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. “Since the strongest predictor of severe COVID-19 is ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Starting this year, drugmakers were set to increase prices on at least 250 brand-name medications, according to data analyzed by healthcare research firm 3 Axis Advisors and reported by Reuters. One ...
The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. Paxlovid is a prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback